Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
Multiple sclerosis: clinical aspects
A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …
of multiple sclerosis patients. Future research will enable the development of more accurate …
Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Background Multiple sclerosis is the most common inflammatory neurological disease in
young adults. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) …
young adults. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) …
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell… - Annals of …, 2011 - Wiley Online Library
New evidence and consensus has led to further revision of the McDonald Criteria for
diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of …
diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
Chapter 11: Genome-wide association studies
Genome-wide association studies (GWAS) have evolved over the last ten years into a
powerful tool for investigating the genetic architecture of human disease. In this work, we …
powerful tool for investigating the genetic architecture of human disease. In this work, we …
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[HTML][HTML] A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
L Kappos, EW Radue, P O'Connor… - … England Journal of …, 2010 - Mass Medical Soc
Background Oral fingolimod, a sphingosine-1-phosphate–receptor modulator that prevents
the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end …
the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end …
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
In patients presenting with a clinically isolated syndrome, MRI can support and substitute
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination …
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination …